Chinese gene testing business AmCare Genomics Lab has raised RMB110 million ($16 m) in Series B funding led by Green Pine Capital Partners. This comes four months after the company closed an extended Series A round of RMB30 million.
Founded in 2015, Guangzhou-based Amcare focuses on the diagnosis of single-gene genetic diseases in order to prevent birth defects. It claims to deliver "the last mile of the clinical application of genomic...
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.